首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial
【2h】

Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial

机译:芪参颗粒在慢性心力衰竭患者中的​​安全性和有效性:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundChronic heart failure (CHF), the final stage of various cardiovascular diseases, is a major public health problem resulting in significant hospitalization rates, mortality, and huge health care costs despite advances in the treatment and management of heart failure and heart failure-related risk factors. Qishen granules (QSG), a Chinese herbal formula, is widely used by traditional Chinese medicine (TCM) practitioners to treat CHF. Several animal experimental studies have showed that QSG can significantly relieve the heart failure symptoms in CHF rat models. However, there is as yet no standard clinical trial to confirm this. Thus, the investigators are conducting this study to evaluate the efficacy and safety of QSG in a large, and varied population.
机译:背景慢性心力衰竭(CHF)是各种心血管疾病的最后阶段,是一个重大的公共卫生问题,尽管在心力衰竭和与心力衰竭相关的风险的治疗和管理方面取得了进步,但仍导致显着的住院率,死亡率和巨大的医疗费用因素。七神颗粒(QSG)是一种中草药配方,被中医(TCM)医师广泛用于治疗CHF。多项动物实验研究表明,QSG可以显着缓解CHF大鼠模型的心力衰竭症状。但是,目前尚无标准的临床试验来证实这一点。因此,研究人员正在进行这项研究,以评估QSG在众多人群中的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号